

Lymphomas and myeloma

28

Hodgkin Lymphoma with Vertebral Involvement

C. Ogilvie*, K. Lund, P. McKay, M. Leach. ¹The Beatson West of Scotland Cancer Centre, Department of Haemato-Oncology, Glasgow, United Kingdom

A 39 year old male presented with a 3 month history of progressive anterior chest pain radiating posteriorly. In addition he had interscapular discomfort exacerbated by alcohol. He had significant weight loss (5kg in one month) and occasional drenching night sweats. There was no palpable lymphadenopathy or organomegaly. CT scan showed mediastinal lymphadenopathy and destruction of T2 and T3 vertebral bodies with an associated soft tissue paravertebral mass (image available). Mediastinal biopsy yielded a diagnosis of nodular sclerosing Hodgkin lymphoma (HL). Bone marrow trephine showed no evidence of infiltration. PET/CT confirmed bone involvement at T2/T3 making him a stage 4B. He had a Hasenclever score of 2. He was entered into the NCRI RATHL study for advanced HL. PET/CT scan after 2 cycles of ABVD showed no abnormal FDG uptake and he therefore went on to complete a total of 6 cycles of therapy. End of treatment CT scan showed resolution of adenopathy and the paraspinal mass but residual destruction of T2/T3 vertebrae. Interscapular pain persisted on exertion but was not affected by alcohol ingestion. He received consolidation radiotherapy (30 Gy in 15 fractions) to T1-T4 vertebral bodies. The patient remains well without B symptoms after 4 months of follow up. Potential points for discussion: 1. Should we worry unduly when Hodgkin lymphoma involves bone? 2. Is interim PET scanning still reliable in assessing bony involvement? 3. Is consolidation radiotherapy to bone justified in the setting of a negative interim PET?

29

Pleural effusion in a patient with Hodgkin's lymphoma

I. Faustino¹*, L. Viterbo², A. Rodrigues¹, Â. Oliveira³, J.M. Mariz². ¹Instituto Português de Oncologia do Porto Francisco Gentil, Department of Medical Oncology, Porto, Portugal, ²Instituto Português de Oncologia do Porto Francisco Gentil, Department of Haemato-Oncology, Porto, Portugal, ³Instituto Português de Oncologia do Porto Francisco Gentil, Department of Radiotherapy, Porto, Portugal

A 28-year-old man was admitted at hospital in December 2009, with a 2 months story of left cervical and scapular disabling pain which was exacerbated with superior limb movements. He had Hodgkin's lymphoma (HL), sclerosis nodular type, stage IV-B, IPS-4, and he has been treated with multiple chemotherapy regimens and cervical radiotherapy (May-June/2009). At hospital admission, he was on the 5th cycle of 4th line chemotherapy with Gemcitabine, Vincristine and Liposomal Doxorubicin (GVD). We suspected of disease progression, but PET showed no abnormal uptake. However, TC images revealed a pleural effusion (PE) in the superior left and inter-cisural pleural space. A thoracentesis was performed, with drainage of 650ml yellow-citrine fluid. Laboratory tests revealed an exsudate without lipid excess, bacteriological and mycological tests were negative and no malignant cells were seen. Pleural biopsy showed no neoplastic cells. Central venous catheter (CVC) was removed and had no loss of integrity. As we have excluded infectious and malignant underlying conditions as well as CVC rupture, we thought that the PE could be secondary to radiation or to liposomal doxorubicin (LD) or both. We asked our patient

again and realized that pain had been progressive, starting after the 2nd GVD cycle. Initially, the pain occurred only 2-3 days after chemotherapy, becoming persistent after the 4th cycle. The pain didn't overcome with corticosteroids and opioids, but it improved with anti-inflammatory drugs. The hypothesis of PE being secondary to synergism of LD and radiotherapy seemed probable, regarding the patient's complains. So, the 6th cycle (the last one) was made without doxorubicin and pain has decreased progressively. We presented this case because the diagnosis was difficult, as there are many possible etiologies for a PE in a patient with cancer doing chemotherapy. Management was also controversial, as not prescribing LD at 6th cycle could be questionable.

30

Peripheral T cell Lymphoma – Lennert's subtype

C. Ogilvie*, K. Lund, M. Leach, P. McKay. ¹The Beatson West of Scotland Cancer Centre, Department of Haemato-Oncology, Glasgow, United Kingdom

59 year old male presented in July 2006 with widespread lymphadenopathy. There were no B symptoms or organomegaly. Full blood count was normal but LDH raised. CT scan showed extensive lymphadenopathy and mild splenomegaly. Lymph node biopsy showed a lympho-epithelial T cell lymphoma of Lennert's subtype. Bone marrow was infiltrated making him a stage 4A. He initially declined treatment but commenced CHOP 3 months later in view of increasing peripheral lymphadenopathy with most nodes 3-4cm. Following the third cycle he suffered a myocardial infarction. For the remaining chemotherapy etoposide replaced doxorubicin. Post treatment CT showed mild, low volume lymphadenopathy. Eight months later he developed a florid, infiltrative rash across his torso (image available). Biopsy confirmed peripheral T cell lymphoma with identical peak in T cell receptor gene rearrangement as that seen in initial biopsy. One month later he developed recurrent lymphadenopathy and stage 4 relapse was confirmed. He was treated with DHAP salvage chemotherapy with a view to autologous stem cell transplant. However despite an excellent response we deferred transplant as he was profoundly debilitated. Within 3 months the skin rash recurred followed by B symptoms and progressive lymphadenopathy and splenomegaly. LDH was raised but full blood count was normal. Twelve days later he developed severe thrombocytopenia and LDH increased dramatically. Severe pancytopenia ensued and bone marrow aspirate showed marked haemophagocytosis (image available). Despite treatment with high dose steroids, his condition continued to deteriorate. He died one week later. Potential points for discussion: Is Lennerts lymphoma a clinically distinct subtype of peripheral T cell lymphoma? What is the optimum first line treatment for Lennerts lymphoma? Is there a role for gemcitabine in the management of peripheral T cell lymphoma? Should patients with peripheral T cell lymphoma be transplanted in first remission?

31

Peripheral T-cell lymphoma (PTCL), CMV or both?

A.C. Pinto¹*, I.C. Rodrigues Ferreira², I. Moreira², M. Mariz². ¹Portuguese Oncology Institute of Coimbra, Department of Medical Oncology, Porto, Portugal, ²Portuguese Oncology Institute of Porto, Department of Hemato Oncology, Porto, Portugal

41-year-old male (past exposure to toxic paints, smoker) who began complaints of fever, sweating, cervical lymphadenopathy and hepatosplenomegaly (HSM), cutaneous rash, generalized pruritus and autoimmune hemolytic anemia (AIHA) in 06/2006. He had recurrent episodes with partial improvement on corticosteroids; was referred to our hospital in 05/2009:

PE revealed cervical lymphadenopathies (2×2 cm), decreased breath sounds on left chest and non-tender hepatomegaly. PET scan: upper and lower diaphragmatic lymph node involvement, lung, muscle and bone. Normal bone marrow (BM) biopsy. Lymph node histopathology showed a PTCL NOS. Classification: stage IVB disease. Treatment proposal: $6 \times$ CHOP, followed by ASCT if CR. Clinically improved but PET evaluation showed residual lymphoma. He was started on 2nd line CT with Alemtuzumab-ICE (M-ICE). During 2nd cycle he developed fever, pruritus, sweating, tender hepatosplenomegaly, mild jaundice and pancytopenia with remark of severe hemolytic anemia and elevated LFTs. Microbiology studies documented reactivation of CMV infection. Steroids and valganciclovir were given. CT response evaluation PET: splenomegaly with ^{18}F -FDG hypermetabolic activity superior to liver and increased BM positivity. We repeated BM biopsy, which was positive for the previously diagnosed NHL. This was interpreted as disease progression and we halted the ongoing CT and started palliative treatment with oral Etoposide and low dose steroids. Patient has been doing well, with resolution of the CMV infection and stable hematological parameters. This case illustrates the difficult treatment decisions regarding PTLC patients, due to their poor prognosis and treatment response. An additional challenge was the differential diagnosis of infection vs. disease progression considering the onset and similarity of symptoms. This patient had disease progression, though at the moment is symptom-free on palliative ambulatory CT.